MA29678B1 - Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis - Google Patents

Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis

Info

Publication number
MA29678B1
MA29678B1 MA30313A MA30313A MA29678B1 MA 29678 B1 MA29678 B1 MA 29678B1 MA 30313 A MA30313 A MA 30313A MA 30313 A MA30313 A MA 30313A MA 29678 B1 MA29678 B1 MA 29678B1
Authority
MA
Morocco
Prior art keywords
tuberculosis infection
fusion protein
preventing
treating
mtb72f
Prior art date
Application number
MA30313A
Other languages
English (en)
French (fr)
Inventor
Rhea Coler
Yves Lobet
Steven Reed
Original Assignee
Infectious Disease Res Inst Idri
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst Idri, Glaxosmithkline Biolog Sa filed Critical Infectious Disease Res Inst Idri
Publication of MA29678B1 publication Critical patent/MA29678B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA30313A 2005-04-29 2007-10-25 Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis MA29678B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67654905P 2005-04-29 2005-04-29
US77701706P 2006-02-27 2006-02-27

Publications (1)

Publication Number Publication Date
MA29678B1 true MA29678B1 (fr) 2008-08-01

Family

ID=36972897

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30313A MA29678B1 (fr) 2005-04-29 2007-10-25 Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis

Country Status (24)

Country Link
US (6) US8470338B2 (enExample)
EP (3) EP2457926B1 (enExample)
JP (4) JP5164830B2 (enExample)
KR (4) KR101352806B1 (enExample)
CN (3) CN106390108B (enExample)
AT (1) ATE543832T1 (enExample)
AU (1) AU2006243357B2 (enExample)
BR (1) BRPI0611347A2 (enExample)
CA (2) CA2821389C (enExample)
CY (1) CY1112851T1 (enExample)
DK (3) DK2457926T3 (enExample)
EA (1) EA012576B1 (enExample)
ES (3) ES2381492T3 (enExample)
HR (3) HRP20120331T1 (enExample)
IL (2) IL186654A (enExample)
MA (1) MA29678B1 (enExample)
NO (3) NO340766B1 (enExample)
NZ (1) NZ562729A (enExample)
PH (1) PH12013502449A1 (enExample)
PL (3) PL2457926T3 (enExample)
PT (3) PT2426141E (enExample)
SI (3) SI2426141T1 (enExample)
WO (1) WO2006117240A2 (enExample)
ZA (1) ZA200709209B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2457926T3 (pl) * 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP1994409A2 (en) * 2006-03-14 2008-11-26 Oregon Health and Science University Methods for producing an immune response to tuberculosis
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
WO2009025820A2 (en) * 2007-08-21 2009-02-26 Stc. Unm Rationally improved isoniazid and ethionamide derivatives and activity through selective isotopic substitution
WO2009158284A2 (en) * 2008-06-26 2009-12-30 Mayo Foundation For Medical Education And Research Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
EP2315597B1 (en) 2008-07-25 2017-08-23 GlaxoSmithKline Biologicals S.A. Novel compositions and methods
UA107330C2 (uk) 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування
WO2010010179A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CN102413837B (zh) 2009-04-24 2015-11-25 国立血清研究所 预防再激活的结核病tb疫苗
PL2528621T3 (pl) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
HUE028452T2 (en) 2010-12-14 2016-12-28 Glaxosmithkline Biologicals Sa Mycobacterium antigenic preparations
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
PL2661253T3 (pl) * 2011-01-04 2017-08-31 Archivel Farma, Sl Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
ES2670493T3 (es) 2012-01-12 2018-05-30 Archivel Farma, S.L. Vacuna de MTB-C contra respuestas alérgicas
WO2014042780A1 (en) * 2012-08-03 2014-03-20 Infectious Disease Research Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
WO2014047848A1 (en) * 2012-09-27 2014-04-03 Chengdu Yongan Pharmaceutical Co., Ltd. Modified bcg strains with reduced or eliminated activity of lsr2 and pharmaceutical composition comprising same
CN102994595B (zh) * 2012-11-30 2018-10-26 广州白云山拜迪生物医药有限公司 一种融合蛋白包涵体的制备方法
CN102993266B (zh) * 2012-11-30 2019-08-23 广州白云山拜迪生物医药有限公司 一种融合蛋白的纯化和复性方法
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10335374B2 (en) 2014-12-04 2019-07-02 University System of Georgia, Valdosta State University Tablet composition for anti-tuberculosis antibiotics
CN107615047A (zh) * 2015-04-02 2018-01-19 比奥德赛公司 利用表面选择性非线性光学技术确定蛋白质结构的方法
US10653679B2 (en) 2015-05-04 2020-05-19 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting bacterial growth
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN110035770B (zh) 2016-12-07 2023-06-16 葛兰素史密丝克莱恩生物有限公司 新方法
WO2019178472A1 (en) * 2018-03-16 2019-09-19 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
US11717519B2 (en) 2017-04-21 2023-08-08 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
WO2022119899A1 (en) * 2020-12-02 2022-06-09 Shionogi & Co., Ltd. A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin
TW202328167A (zh) 2021-08-31 2023-07-16 美商維爾生物科技股份有限公司 結核病疫苗
KR102534846B1 (ko) 2021-12-14 2023-05-19 재단법인 환동해산업연구원 결핵균에 항균 활성을 가지는 해조류 추출물
CN116162141B (zh) * 2022-11-30 2024-04-12 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原epcra013及其应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DE69126620T2 (de) 1990-10-18 1997-10-02 Cellpro Inc Vorrichtung und verfahren zur trennung von partikeln mittels eines biegsamen gefässes
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
EP0598816B1 (en) 1991-08-15 1999-06-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
DE69312487T2 (de) 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
WO1994015635A1 (en) 1993-01-11 1994-07-21 Dana-Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5551622A (en) 1994-07-13 1996-09-03 Yoon; Inbae Surgical stapler
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
ES2378051T3 (es) 1995-09-01 2012-04-04 Corixa Corporation Compuestos y métodos para el diagnóstico de la tubercolosis.
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
DK1398379T3 (da) 1995-09-01 2007-01-08 Corixa Corp Forbindelser og fremgangsmåder til immunterapi og diagnose af tuberkulose
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
IL129389A0 (en) 1996-10-11 2000-02-17 Corixa Corp Compounds and methods for diagnsosis of tuberculosis
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US5655998A (en) 1996-12-03 1997-08-12 Yu; Chih-An Space walking exerciser
CA2284586C (en) 1997-04-01 2011-02-08 Ribi Immunochem Research, Inc. Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE69942214D1 (de) 1998-02-05 2010-05-12 Glaxosmithkline Biolog Sa Verfahren zur Reinigung oder Herstellung der MAGE Protein
WO1999051748A2 (en) 1998-04-07 1999-10-14 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
JP2003510370A (ja) 1999-10-07 2003-03-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
AU6867801A (en) * 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
US20030143240A1 (en) 2000-06-27 2003-07-31 Cabezon-Silva Teresa Elisa Virginia Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen
AU2002303135A1 (en) * 2001-03-13 2002-09-24 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
WO2003072633A1 (en) 2002-02-14 2003-09-04 Mitsui Chemicals, Inc. Polyester resin and catalyst for polyester production, process for producing polyester resin with the catalyst, polyester resin obtained with the catalyst, and hollow molded container comprising the polyester resin
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1846931A1 (en) 2005-01-19 2007-10-24 Panduit Corporation Communication channels with suppression cores
PL2457926T3 (pl) * 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
JP4468858B2 (ja) 2005-06-01 2010-05-26 オリンパスイメージング株式会社 データ符号化装置、データ符号化方法、プログラム
US7296798B2 (en) 2006-01-31 2007-11-20 Matt Overfield Gameboard, games played on board and methods of play requiring strategy and luck
CN102413837B (zh) 2009-04-24 2015-11-25 国立血清研究所 预防再激活的结核病tb疫苗
US8567987B2 (en) 2009-07-21 2013-10-29 Cooper Technologies Company Interfacing a light emitting diode (LED) module to a heat sink assembly, a light reflector and electrical circuits
HUE028452T2 (en) 2010-12-14 2016-12-28 Glaxosmithkline Biologicals Sa Mycobacterium antigenic preparations
US9119754B2 (en) 2011-10-08 2015-09-01 Michael Dennis Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure
US9051890B2 (en) 2013-10-28 2015-06-09 Ford Global Technologies, Llc Method for estimating charge air cooler condensation storage with an intake oxygen sensor
US9903268B2 (en) 2015-04-02 2018-02-27 Ford Global Technologies, Llc Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine
US9810514B2 (en) 2015-09-08 2017-11-07 Deufol Sunman Inc. Ammunition carrier consumer package

Also Published As

Publication number Publication date
CN102617739A (zh) 2012-08-01
AU2006243357B2 (en) 2012-03-15
PL2457926T3 (pl) 2015-03-31
KR20130110233A (ko) 2013-10-08
JP5659207B2 (ja) 2015-01-28
KR20080021624A (ko) 2008-03-07
JP2008539187A (ja) 2008-11-13
PT2457926E (pt) 2014-11-25
EP2457926B1 (en) 2014-09-24
EP2426141A3 (en) 2012-08-15
SI1877426T1 (sl) 2012-06-29
US10105430B2 (en) 2018-10-23
NO20141158L (no) 2008-01-25
SI2457926T1 (sl) 2015-01-30
US9655958B2 (en) 2017-05-23
CA2821389A1 (en) 2006-11-09
US20090123491A1 (en) 2009-05-14
KR20150036658A (ko) 2015-04-07
NO340206B1 (no) 2017-03-20
HRP20141184T1 (en) 2015-03-13
US10350283B2 (en) 2019-07-16
CA2821389C (en) 2015-11-17
PT1877426E (pt) 2012-05-02
DK1877426T3 (da) 2012-05-14
EP1877426B1 (en) 2012-02-01
EA200702081A1 (ru) 2008-04-28
JP5164830B2 (ja) 2013-03-21
US20190307872A1 (en) 2019-10-10
BRPI0611347A2 (pt) 2010-08-31
NZ562729A (en) 2009-10-30
AU2006243357A1 (en) 2006-11-09
CN101273055B (zh) 2016-03-16
SI2426141T1 (sl) 2015-01-30
CY1112851T1 (el) 2016-02-10
EP2426141A2 (en) 2012-03-07
US9056913B2 (en) 2015-06-16
NO20075201L (no) 2008-01-25
CA2607715C (en) 2015-11-24
PL2426141T3 (pl) 2015-02-27
CN101273055A (zh) 2008-09-24
JP2013040190A (ja) 2013-02-28
PL1877426T3 (pl) 2012-10-31
IL186654A0 (en) 2008-01-20
NO20120381L (no) 2008-01-25
EP2426141B1 (en) 2014-10-01
KR101352806B1 (ko) 2014-02-17
NO340766B1 (no) 2017-06-19
US20140050776A1 (en) 2014-02-20
EP1877426A2 (en) 2008-01-16
CN106390108A (zh) 2017-02-15
JP2015057403A (ja) 2015-03-26
EP2457926A1 (en) 2012-05-30
PH12013502449A1 (en) 2015-12-14
JP2012065650A (ja) 2012-04-05
DK2426141T3 (da) 2014-11-10
IL215112A0 (en) 2011-10-31
KR20120089475A (ko) 2012-08-10
US20150231224A1 (en) 2015-08-20
HRP20141125T1 (hr) 2015-01-02
WO2006117240A2 (en) 2006-11-09
ES2524570T3 (es) 2014-12-10
DK2457926T3 (da) 2015-01-05
IL215112A (en) 2013-07-31
CN106390108B (zh) 2020-09-08
US20170196961A1 (en) 2017-07-13
IL186654A (en) 2013-04-30
PT2426141E (pt) 2014-11-25
ATE543832T1 (de) 2012-02-15
HRP20120331T1 (hr) 2012-05-31
ES2381492T3 (es) 2012-05-28
ZA200709209B (en) 2009-12-30
US8470338B2 (en) 2013-06-25
US20170065696A9 (en) 2017-03-09
US10639361B2 (en) 2020-05-05
US20190030154A1 (en) 2019-01-31
WO2006117240A3 (en) 2007-01-18
ES2524572T3 (es) 2014-12-10
NO345071B1 (no) 2020-09-14
EA012576B1 (ru) 2009-10-30
CA2607715A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
MA29678B1 (fr) Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis
BR112022015626A2 (pt) Composição e métodos de vacinas de mrna contra infecção de novo coronavírus
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
BR0211742A (pt) Derivados de aminoisoxazole ativos como inibidores de cinase
CY1110886T1 (el) Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση
BRPI0415816A (pt) composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
MA27699A1 (fr) Vaccin contre vhc
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
FR2870126A1 (fr) Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
BRPI0506493A (pt) combinações terapêuticas
Antos et al. IFNλ: balancing the light and dark side in pulmonary infection
UA98605C2 (ru) Новый способ предотвращения или лечения инфекции m. tuberculosis
BR0209985A (pt) Composto e método para o tratamento de um paciente
ATE530565T1 (de) Impfstoff zur prävention und behandlung von progressiver atrophischer rhinitis in schweinen
DE60236443D1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
CY1115823T1 (el) Νεα μεθοδος προληψης ή θεραπειας μολυνσης m. tuberculosis
EA200101171A1 (ru) Способ лечения инфекций, вызванных streptococcus pneumoniae
BR0307196A (pt) Idraparinux (sanorg 34006) para tratamento e profilaxia secundária de eventos tromboembólicos venosos em pacientes com trombose venosa profunda
BR0316556A (pt) Compostos, processo para a preparação de um composto, composição farmacêutica que compreende esse composto, sua utilização e método para o tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas ppar(alfa) e/ou ppary
TH86014A (th) สารผสมที่ประกอบด้วยปิปเปอราซิลลินและทาโซแบคแทมที่มีประโยชน์สำหรับการฉีด
TH1701007800A (th) ตัวยับยั้งเมทัลโล-บีตา-แลคทาเมส